Astria Therapeutics inc   (ATXS)
Other Ticker:  

Astria Therapeutics Inc 's



ATXS Sales vs. its Competitors Q1 2024

Revenue Growth Comparisons

Net Income Comparison

<<  ATXS Stock Performance Comparisons

*Market share is calculated based on total revenue.

  News about Astria Therapeutics inc Contracts

Advances in the Development of Monoclonal Antibody Inhibitors for Hereditary Angioedema: A Promising Case Study of Astria Therapeutics' STAR-0215

Abstract:This article provides an in-depth analysis of the positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. The study, conducted by Astria Therapeutics, Inc., a biopharmaceutical company dedicated to developing innovative therapies for allergic and immunological diseases, has demonstrated a favorable safety and tolerability profile, along with a significant reduction in mean monthly attacks of HAE. 1. Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of localized swelling, leading to significant morbidity and poten...

Who are Astria Therapeutics inc 's Competitors?


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com